Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 3,920 | 339 | 3,551 |
| Samples | 751 | 105 | 639 |
| Peptides | 462 | 72 | 404 |
Function
CHAT · Choline O-acetyltransferase
This gene encodes an enzyme which catalyzes the biosynthesis of the neurotransmitter acetylcholine. This gene product is a characteristic feature of cholinergic neurons, and changes in these neurons may explain some of the symptoms of Alzheimer's disease. Polymorphisms in this gene have been associated with Alzheimer's disease and mild cognitive impairment. Mutations in this gene are associated with congenital myasthenic syndrome associated with episodic apnea. Multiple transcript variants encoding different isoforms have been found for this gene, and some of these variants have been shown to encode more than one isoform. [provided by RefSeq, May 2010].
Isoforms & Proteins
6 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 427 amino-acid changes on canonical ENST00000337653 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CHAT · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CHAT – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| Other Solid Cancers | 3/94 3% | 71/1515 5% |
| Melanoma | 11/210 5% | 86/1899 5% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 6/133 5% |
| Small Cell Lung Carcinoma | 0/9 0% | 27/752 4% |
| Endometrial Carcinoma | 7/42 17% | 15/612 2% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 87/2550 3% |
| Acute Myeloid Leukemia | 3/90 3% | 0/0 0% |
| Squamous Cell Lung Carcinoma | 3/57 5% | 24/810 3% |
| Non-Small Cell Lung Carcinoma | 8/304 3% | 42/1390 3% |
| Colorectal Carcinoma | 17/143 12% | 79/3239 2% |
| Unknown | 1/10 10% | 0/29 0% |
| T-Lymphoblastic Leukemia | 1/40 2% | 0/0 0% |
| Gastric Carcinoma | 3/74 4% | 40/1809 2% |
| Hodgkins Lymphoma | 0/16 0% | 3/122 2% |
| Neuroendocrine Tumour | 12/154 8% | 3/577 1% |
| Rhabdomyosarcoma | 0/33 0% | 4/171 2% |
| Oral Cavity Carcinoma | 1/54 2% | 0/0 0% |
| Cervical Carcinoma | 1/35 3% | 6/422 1% |
| Other Sarcomas | 8/69 12% | 1/699 0% |
| Bladder Carcinoma | 1/58 2% | 10/956 1% |
| Head and Neck Carcinoma | 3/85 4% | 14/1574 1% |
| Non-Cancerous | 0/104 0% | 9/830 1% |
| Glioma | 0/52 0% | 20/2127 1% |
| Hepatocellular Carcinoma | 3/46 7% | 17/2210 1% |
| Esophageal Carcinoma | 0/23 0% | 7/769 1% |
| Mesothelioma | 2/62 3% | 0/165 0% |
| Adrenocortical Carcinoma | 0/3 0% | 1/112 1% |
| Thyroid Gland Carcinoma | 2/45 4% | 12/1592 1% |
| Pancreatic Carcinoma | 2/89 2% | 12/1611 1% |
| Prostate Carcinoma | 2/13 15% | 15/2105 1% |
Mutation Distribution
Where CHAT is mutated · all tissues, split by cell line vs tissue
How many mutations in CHAT were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 16 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 3,920 mutations in CHAT
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|